{
  "guideline": {
    "id": "PA166104982",
    "name": "Annotation of DPWG Guideline for amitriptyline and CYP2D6",
    "source": "DPWG",
    "version": 32,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104982",
    "relatedChemicals": [
      {
        "id": "PA448385",
        "name": "amitriptyline",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166301823",
      "name": "Recommendation Annotation PA166301823",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103290,
        "html": "<p>Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</p>\n"
      },
      "implications": [
        "The risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301968",
      "name": "Recommendation Annotation PA166301968",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103487,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301941",
      "name": "Recommendation Annotation PA166301941",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103460,
        "html": "<p>The guideline does not provide a recommendation for amitriptyline in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301963",
      "name": "Recommendation Annotation PA166301963",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103482,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301862",
      "name": "Recommendation Annotation PA166301862",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103321,
        "html": "<p>Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</p>\n"
      },
      "implications": [
        "The risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301901",
      "name": "Recommendation Annotation PA166301901",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103420,
        "html": "<p>The guideline does not provide a recommendation for amitriptyline in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301861",
      "name": "Recommendation Annotation PA166301861",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103320,
        "html": "<p>Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</p>\n"
      },
      "implications": [
        "The risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301967",
      "name": "Recommendation Annotation PA166301967",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103486,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301966",
      "name": "Recommendation Annotation PA166301966",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103485,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301962",
      "name": "Recommendation Annotation PA166301962",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103481,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301965",
      "name": "Recommendation Annotation PA166301965",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103484,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301842",
      "name": "Recommendation Annotation PA166301842",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103308,
        "html": "<p>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</p>\n"
      },
      "implications": [
        "In theory risk of side effects is increased, because the genetic variation results in higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301961",
      "name": "Recommendation Annotation PA166301961",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103480,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301921",
      "name": "Recommendation Annotation PA166301921",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103440,
        "html": "<p>The guideline does not provide a recommendation for amitriptyline in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301881",
      "name": "Recommendation Annotation PA166301881",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103400,
        "html": "<p>The guideline does not provide a recommendation for amitriptyline in normal metabolizers</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301942",
      "name": "Recommendation Annotation PA166301942",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103461,
        "html": "<p>The guideline does not provide a recommendation for amitriptyline in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301964",
      "name": "Recommendation Annotation PA166301964",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103483,
        "html": "<p>Increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites. Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\nIf a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased. The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301863",
      "name": "Recommendation Annotation PA166301863",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448385",
          "name": "amitriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103322,
        "html": "<p>Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</p>\n"
      },
      "implications": [
        "The risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}